Aileron Therapeutics Stock Performance

ALRN Stock  USD 6.93  1.23  21.58%   
Aileron Therapeutics holds a performance score of 16 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.97, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Aileron Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Aileron Therapeutics is expected to outperform it slightly. Use Aileron Therapeutics downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Aileron Therapeutics.

Risk-Adjusted Performance

16 of 100

 
Low
 
High
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Aileron Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Aileron Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
19.91
Five Day Return
22.67
Year To Date Return
122.15
Ten Year Return
(96.79)
All Time Return
(96.79)
Last Split Factor
1:20
Last Split Date
2022-11-11
1
Aileron Therapeutics Inc has fallen -1.56 percent in a Week, Should You Accumulate - InvestorsObserver
01/23/2024
2
Aileron Therapeutics files to sell 7.06M shares for holders
01/29/2024
3
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
02/01/2024
4
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader ...
02/15/2024
5
Acquisition by Armen Shanafelt of 20000 shares of Aileron Therapeutics subject to Rule 16b-3
02/23/2024
6
Aileron Therapeutics Shareholders Approve Major Stock Proposals - TipRanks.com - TipRanks
02/29/2024
7
Disposition of tradable shares by James Windsor of Aileron Therapeutics subject to Rule 16b-3
03/05/2024
8
Aileron Therapeutics names Brian Windsor as new CEO and President
03/12/2024
9
Head to Head Comparison Aileron Therapeutics Tonix Pharmaceuticals - Defense World
03/22/2024
Begin Period Cash Flow4.9 M
  

Aileron Therapeutics Relative Risk vs. Return Landscape

If you would invest  305.00  in Aileron Therapeutics on December 29, 2023 and sell it today you would earn a total of  388.00  from holding Aileron Therapeutics or generate 127.21% return on investment over 90 days. Aileron Therapeutics is currently generating 1.645% in daily expected returns and assumes 7.6816% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Aileron, and 68% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Aileron Therapeutics is expected to generate 13.4 times more return on investment than the market. However, the company is 13.4 times more volatile than its market benchmark. It trades about 0.21 of its potential returns per unit of risk. The NYSE Composite is currently generating roughly 0.23 per unit of risk.

Aileron Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Aileron Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aileron Therapeutics, and traders can use it to determine the average amount a Aileron Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.2141

Best PortfolioBest Equity
Good Returns
Average ReturnsALRN
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 7.68
  actual daily
67
67% of assets are less volatile

Expected Return

 1.65
  actual daily
32
68% of assets have higher returns

Risk-Adjusted Return

 0.21
  actual daily
16
84% of assets perform better
Based on monthly moving average Aileron Therapeutics is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aileron Therapeutics by adding it to a well-diversified portfolio.

Aileron Therapeutics Fundamentals Growth

Aileron Stock prices reflect investors' perceptions of the future prospects and financial health of Aileron Therapeutics, and Aileron Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aileron Stock performance.

About Aileron Therapeutics Performance

To evaluate Aileron Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Aileron Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Aileron Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Aileron Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Aileron's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Return On Capital Employed(1.34)(1.40)
Return On Assets(1.10)(1.16)
Return On Equity(1.67)(1.75)

Things to note about Aileron Therapeutics performance evaluation

Checking the ongoing alerts about Aileron Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aileron Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Aileron Therapeutics is way too risky over 90 days horizon
Aileron Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (12.94 M) with loss before overhead, payroll, taxes, and interest of (17.01 M).
Aileron Therapeutics currently holds about 32.38 M in cash with (13.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Aileron Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 63.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Head to Head Comparison Aileron Therapeutics Tonix Pharmaceuticals - Defense World
Evaluating Aileron Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Aileron Therapeutics' stock performance include:
  • Analyzing Aileron Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aileron Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Aileron Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Aileron Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aileron Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Aileron Therapeutics' stock. These opinions can provide insight into Aileron Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Aileron Therapeutics' stock performance is not an exact science, and many factors can impact Aileron Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Aileron Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aileron Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aileron Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aileron Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Aileron Stock analysis

When running Aileron Therapeutics' price analysis, check to measure Aileron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aileron Therapeutics is operating at the current time. Most of Aileron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aileron Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aileron Therapeutics' price. Additionally, you may evaluate how the addition of Aileron Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Commodity Directory
Find actively traded commodities issued by global exchanges
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Is Aileron Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.85)
Return On Assets
(0.40)
Return On Equity
(0.76)
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.